Sei Investments Co. Acquires 31,945 Shares of Prestige Consumer Healthcare Inc. $PBH

Sei Investments Co. increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 192,678 shares of the company’s stock after buying an additional 31,945 shares during the period. Sei Investments Co.’s holdings in Prestige Consumer Healthcare were worth $11,420,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the stock. Lido Advisors LLC increased its holdings in Prestige Consumer Healthcare by 5.4% during the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after buying an additional 192 shares during the last quarter. Cerity Partners LLC boosted its stake in Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after acquiring an additional 218 shares during the last quarter. UMB Bank n.a. boosted its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares during the period. Finally, Diversify Advisory Services LLC grew its position in shares of Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after acquiring an additional 256 shares during the period. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

PBH has been the subject of several research analyst reports. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Hold” and an average price target of $70.75.

Insider Buying and Selling

In related news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $50.29 on Friday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $2.38 billion, a PE ratio of 12.86, a P/E/G ratio of 1.61 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $75.63. The company has a 50-day moving average price of $48.30 and a two-hundred day moving average price of $56.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter in the previous year, the business earned $1.32 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).